Clinical TrialID 6876

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

NCT04361708

Pancreatic Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Adenocarcinoma

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
6876
Evidence Id
6876
Core Evidence Id
6876
Source Clinical Trial Id
6868
Herb2 Clinical Trial Id
HBCT006868
Nct Id
NCT04361708
Title
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
Status
Recruiting
Phase
Phase 1
Study Result
No
Study Condition
Pancreatic Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Adenocarcinoma
Study Type
Interventional
Study Design
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Intervention
DRUG: Oxaliplatin|DRUG: Docetaxel|DRUG: Leucovorin|DRUG: Irinotecan|DRUG: 5-Fluorouracil
Intervention Allocation
Non_Randomized
Intervention Model
Parallel
Intervention Mask
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
54
Outcome Measure
The maximum dose tolerated, To determine the maximum tolerated dose in the first month of therapy in each of the three main genotype groups (low, intermediate, and high risk) using genotype-guided dosing of irinotecan as part of the I-FLOAT regimen, 1 month
Sponsor Collaborator
University of Chicago
Funded By
OTHER
Location
The University of Chicago, Chicago, Illinois, 60637, United States
Other Id
IRB19-1292
Start Date
2020-05-08
Primary Completion Date
2025-06
Completion Date
2027-05
First Posted
2020-04-24
Results First Posted
Last Update Posted
2024-09-19
Study Document
Study Url
https://clinicaltrials.gov/study/NCT04361708
Title Cn
Title En
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
Bilingual Status
semi_complete